for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GRAIL Inc

GRAL.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
--
Open
--
Volume
--
3M AVG Volume
0.00
Today's High
--
Today's Low
--
52 Week High
--
52 Week Low
--
Shares Out (MIL)
135.85
Market Cap (MIL)
--
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Illumina & Grail Receives Requests For Additional Information, Materials From U.S. FTC In Connection With Co’S Pending Acquisition Of Grail

Sequencing Firm Illumina To Pay $7.1 Bln For Liquid-Biopsy Firm Grail - WSJ

Illumina Is In Talks To Acquire Cancer-Detection Startup Grail- Bloomberg Reporter Tweet

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GRAIL Inc

GRAIL Inc is a United States-based healthcare company. The Company focuses on developing new technologies for early cancer detection. By leveraging it's platform technology, the Company has developed a multi-cancer early detection blood test that has the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal from a single blood draw. The Company has developed multi-cancer early detection test, Galleri, which is designed as a screening test for asymptomatic individuals over 50 years of age. In addition to Galleri, the Company is utilizing it's technology platform and population-scale studies to introduce a diagnostic aid for cancer test (DAC). DAC is designed to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing a minimal residual disease (MRD) test, designed to enable blood-based detection with or without tissue.

Industry

Biotechnology & Drugs

Contact Info

1525 O'Brien Drive

MENLO PARK, CA

94025

United States

+1.650.7719796

https://grail.com/

Executive Leadership

Catherine J. Friedman

Chair of the Board of Directors

Hans Edgar Bishop

Chief Executive Officer, Director

Jeffrey T. Huber

Vice Chairman of the Board, Founding Chief Executive Officer

Matthew P. Young

Chief Financial Officer, Chief Operating Officer

Hal V. Barron

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up